|

IDRX-42 Clinical Trials

2 actively recruiting trials across 2 locations

No change since May 2026

Also known as: GSK6042981, velzatinib - subject to USAN approval

Pipeline

Phase 1: 1Phase 3: 1

Top Sponsors

  • IDRX, Inc., a wholly owned subsidiary of GSK, LLC1
  • GlaxoSmithKline1

Indications

  • Gastrointestinal Neoplasms2
  • Cancer2
  • Digestive System Disease1
  • Gastrointestinal Diseases1
  • Metastatic Cancer1

Phoenix, Arizona1 trial

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

GSK Investigational Site

Phase 3

Miami, Florida1 trial

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

GSK Investigational Site

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.